Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) shares fell 5.9% during mid-day trading on Wednesday . The company traded as low as $25.30 and last traded at $25.13. 15,072 shares were traded during mid-day trading, a decline of 95% from the average session volume of 293,713 shares. The stock had previously closed at $26.70.
Analyst Ratings Changes
Several brokerages have recently weighed in on ASTH. Bank of America lowered their price target on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Barclays initiated coverage on shares of Astrana Health in a report on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 target price on the stock. Robert W. Baird cut their price target on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Finally, Truist Financial reduced their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $53.29.
View Our Latest Stock Report on ASTH
Astrana Health Trading Down 5.7%
The business's 50-day simple moving average is $27.62 and its two-hundred day simple moving average is $31.43. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of 34.98, a PEG ratio of 1.35 and a beta of 0.85. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 0.54.
Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.23 by ($0.09). The company had revenue of $620.39 million for the quarter, compared to analysts' expectations of $628.11 million. Astrana Health had a return on equity of 4.90% and a net margin of 1.56%. The business's revenue for the quarter was up 53.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.31 EPS. Equities analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current year.
Hedge Funds Weigh In On Astrana Health
Several institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB boosted its position in Astrana Health by 4.7% in the 4th quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company's stock valued at $281,000 after buying an additional 400 shares during the period. Quarry LP boosted its holdings in Astrana Health by 35.5% in the fourth quarter. Quarry LP now owns 1,799 shares of the company's stock valued at $57,000 after purchasing an additional 471 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Astrana Health by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,505 shares of the company's stock valued at $773,000 after purchasing an additional 915 shares during the period. Swiss National Bank grew its stake in Astrana Health by 1.1% during the 4th quarter. Swiss National Bank now owns 88,444 shares of the company's stock worth $2,789,000 after purchasing an additional 1,000 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Astrana Health by 21.3% during the 1st quarter. US Bancorp DE now owns 5,791 shares of the company's stock worth $180,000 after purchasing an additional 1,015 shares during the period. 52.77% of the stock is owned by institutional investors and hedge funds.
Astrana Health Company Profile
(
Get Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
